Trehalose Formulation for Preventing PABPN1 Aggregation in OPMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no medical treatment or cure for oculopharyngeal muscular dystrophy (OPMD), a rare inherited myopathy characterized by severe dysphagia, ptosis, and progressive muscle weakness, leading to debilitation and increased risk of aspiration pneumonia, with current therapeutic strategies providing only temporary relief.
Innovation Solution
An intravenous aqueous formulation of trehalose is administered to prevent pathological protein aggregation within cells, specifically targeting the abnormal protein PABPN1 associated with OPMD, with a pH of 4.5 to 7.0 and osmolality of 280-330 mOsm/kg, retaining in cells for 48-72 hours.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If surgical interventions are used to alleviate ptosis and dysphagia, then temporary relief is achieved, but the disease progression continues leading to severe difficulty in swallowing and increased mortality risk
Solution Approach 1:
The patent applies preliminary action by administering trehalose before protein aggregation occurs, preventing the formation of toxic aggregates that cause muscle weakness and swallowing difficulties. This preventive approach addresses the root cause rather than providing temporary symptomatic relief through surgery.
Solution Approach 2:
The patent converts the harmful effect of protein aggregation into a beneficial outcome by using trehalose to stabilize proteins and prevent aggregate formation. The abnormal PABPN1 protein that causes disease is transformed into a non-aggregating protein through trehalose treatment, converting the harmful aggregation tendency into a beneficial stable protein state.
2Reliability
If no medical treatment exists for OPMD, then disease progression is uninterrupted, but quality of life deteriorates due to severe dysphagia and muscle weakness
Solution Approach 1:
The patent applies parameter changes by modifying the chemical environment within cells through trehalose administration. Trehalose changes the biochemical parameters by stabilizing protein structures and altering cellular metabolism, thereby preventing disease progression while improving quality of life without requiring surgical interventions.
3Speed
If trehalose is administered intravenously, then rapid cellular uptake and retention is achieved, but formulation stability and safety must be maintained
Solution Approach 1:
The patent applies parameter changes by optimizing the formulation parameters of trehalose for intravenous administration. The formulation is designed with specific pH, osmolality, and concentration levels to ensure rapid cellular uptake while maintaining stability and safety. The rapid administration rate is achieved through controlled IV infusion parameters.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively prevents protein aggregation, alleviating muscle weakness and reducing the formation of pathological skeletal muscle fibers, thereby improving the quality of life for OPMD patients.
Implementation Method 1
Trehalose has been shown to prevent pathological aggregation of proteins within cells
Data Source
AI summary
The present invention alleviates a sign or symptom of an aggregation disease or disorder by administering an aqueous formulation comprising trehalose.